Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • RO6885247: Phase Ib/IIa started

    PTC Therapeutics Inc. (NASDAQ:PTCT), South Plainfield, N.J. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: RO6885247, RG7800 Business: Neurology Molecular target: Survival of motor neuron 2 centromeric (SMN2)…

    Published on 1/19/2015
  • RT002: Phase II started

    Revance Therapeutics Inc. (NASDAQ:RVNC), Newark, Calif. Product: RT002 Business: Dermatology Molecular target: NA Description: Injectable botulinum toxin type A that uses TransMTS peptide technology Indication: Treat …

    Published on 1/19/2015
  • Staph ID/R test: Clinical trial started

    Great Basin Corp. (NASDAQ:GBSN), Salt Lake City, Utah Product: Staph ID/R test Business: Diagnostic Molecular target: NA Description: Rapid, automated DNA multiplex assay combining helicase-dependent amplification with …

    Published on 1/19/2015
  • SYN120: Phase IIa started

    Biotie Therapies Corp. (HSE:BTH1V), Turku, Finland Product: SYN120 Business: Neurology Molecular target: Serotonin (5-HT6) receptor; Serotonin (5-HT2A) receptor Description: Oral dual antagonist of the serotonin (5-HT6)…

    Published on 1/19/2015
  • TKM-PLK1: Completed Phase I/II enrollment

    Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR), Burnaby, B.C. Product: TKM-PLK1 (PLK1424) (TKM-080301) (formerly PLK1 SNALP) Business: Cancer Molecular target: Polo-like kinase 1 (PLK1) (STPK13) Description: Short…

    Published on 1/19/2015
  • ToleroMune cat allergy therapy: Completed Phase III enrollment

    Circassia Pharmaceuticals plc (LSE:CIR), Oxford, U.K. Product: ToleroMune cat allergy therapy, Cat-PAD, Cat-SPIRE Business: Inflammation Molecular target: NA Description: T cell vaccine using ToleroMune T cell epitope …

    Published on 1/19/2015
  • TRV130: Phase IIb started

    Trevena Inc. (NASDAQ:TRVN), King of Prussia, Pa. Product: TRV130 Business: Neurology Molecular target: Mu opioid receptor (MOR) (OPRM1) Description: G protein-biased mu opioid receptor (MOR; OPRM1) ligand Indication: …

    Published on 1/19/2015
  • Anti-NKG2a: Phase Ib/II started

    Innate Pharma S.A. (Euronext:IPH), Marseille, France Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: Anti-NKG2a (IPH 2201, NN8765-3658) (formerly IPH22XX) Business: Cancer Molecular target: Killer cell…

    Published on 1/12/2015
  • C: Phase II started

    Valneva SE (Euronext:VLA; VSE:VLA), Lyon, France Product: C. difficile vaccine (VLA84) (formerly IC84) Business: Infectious Molecular target: NA Description: Recombinant protein vaccine consisting of 2 truncated toxins …

    Published on 1/12/2015
  • CF102: Phase II started

    Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel Product: CF102 Business: Cancer Molecular target: Adenosine A3 receptor (ADORA3) Description: Nucleoside adenosine A3 receptor (ADORA3) agonist …

    Published on 1/12/2015
  • Epi proColon: Clinical trial started

    BioChain Institute Inc., Newark, Calif. Epigenomics AG (Xetra:ECX; OTCQX:EPGNY), Berlin, Germany Product: Epi proColon, Epi proColon 2.0 Business: Diagnostic Molecular target: Septin 9 (SEPT9) Description: Second-…

    Published on 1/12/2015
  • IMO-8400: Phase I/II ongoing

    Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Cambridge, Mass. Product: IMO-8400 Business: Cancer Molecular target: Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8) Description: Toll-like receptor 7 (TLR7), TLR8 and…

    Published on 1/12/2015
  • iSONEP sphingomab: Completed Phase II enrollment

    Lpath Inc. (NASDAQ:LPTN), San Diego, Calif. Product: iSONEP sphingomab Business: Ophthalmic Molecular target: Sphingosine 1-phosphate (S1P) receptor Description: Ocular formulation of humanized mAb against sphingosine 1…

    Published on 1/12/2015
  • KX2-361: Phase I started

    Kinex Pharmaceuticals LLC, Buffalo, N.Y. Xiangxue Pharmaceutical Co. Ltd. (SZSE:300147), Guangzhou, China Product: KX2-361, KX02 Business: Cancer Molecular target: Src Description: Lipophilic dual inhibitor of Src and …

    Published on 1/12/2015
  • LR769: Completed Phase III enrollment

    LFB S.A., Les Ulis, France Product: LR769 Business: Hematology Molecular target: Factor VIIa Description: Recombinant human Factor VIIa (rhFVIIa) Indication: Treat congenital hemophilia A and Beta Endpoint: Bleeding …

    Published on 1/12/2015
  • MultiStem: Completed Phase II enrollment

    Athersys Inc. (NASDAQ:ATHX), Cleveland, Ohio Product: MultiStem Business: Neurology Molecular target: Not applicable Description: Allogeneic multipotent adult progenitor cells (MAPC) obtained from the bone marrow of …

    Published on 1/12/2015
  • NEOD001: Phase III started

    Prothena Corp. plc (NASDAQ:PRTA), Dublin, Ireland Product: NEOD001 Business: Endocrine/Metabolic Molecular target: Amyloid Description: Humanized mAb targeting amyloid Indication: Treat amyloid light-chain (AL) …

    Published on 1/12/2015
  • QGC001: Phase IIa started

    Quantum Genomics Corp. (Euronext:ALQGC), Massy, France Product: QGC001 Business: Cardiovascular Molecular target: NA Description: Aminopeptidase A inhibitor Indication: Treat essential grade I or II hypertension …

    Published on 1/12/2015
  • RVSV-EBOV: Phase I resumed

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: RVSV-EBOV, VSV-ZEBOV Business: Infectious Molecular target: NA Description: Recombinant vesicular …

    Published on 1/12/2015
  • SGN-CD33A: Phase Ib started

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Product: SGN-CD33A Business: Cancer Molecular target: CD33 Description: Humanized mAb against CD33 conjugated to 2 pyrrolobenzodiazepine (PBD) dimer moieties …

    Published on 1/12/2015
  • Suberohydroxamic acid phenyl ester: Phase II started

    TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Product: Suberohydroxamic acid phenyl ester (SHAPE) (formerly SHP-141) Business: Cancer Molecular target: Histone deacetylase (HDAC) Description: Topical gel …

    Published on 1/12/2015
  • WT1 TCR-transduced T cells: Phase I/II started

    Cell Therapy Catapult, London, U.K. Product: WT1 TCR-transduced T cells Business: Cancer Molecular target: Wilms tumor 1 (WT1) Description: Autologous T cell receptor (TCR)-transduced T cells targeting Wilms tumor 1 (…

    Published on 1/12/2015
  • Xyrem sodium oxybate: Phase III started

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Product: Xyrem sodium oxybate (JZP-6) Business: Neurology Molecular target: GABA Beta receptor Description: Oral liquid formulation of the sodium salt of gamma …

    Published on 1/12/2015
  • AC-201: Phase II started

    TWi Pharmaceuticals Holding Inc. (GreTai:4180), Taipei, Taiwan Product: AC-201 Business: Endocrine/Metabolic Molecular target: Interleukin-1 (IL-1) beta; Interleukin-1 (IL-1) receptor antagonist (IL-1RA) Description: …

    Published on 1/5/2015
  • ADI-PEG 20: Phase I started

    Polaris Pharmaceuticals Inc., San Diego, Calif. Product: ADI-PEG 20 Business: Cancer Molecular target: NA Description: Arginine deiminase (ADI) formulated with polyethylene glycol Indication: Treat advanced …

    Published on 1/5/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993